Skip to main content
EVO
NASDAQ Life Sciences

Evotec Nominates New Board Member, Secures Shareholder Cooperation Agreement

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$3.06
Mkt Cap
$1.038B
52W Low
$2.308
52W High
$4.8
Market data snapshot near publication time

summarizeSummary

Evotec SE announced the nomination of Dr. Wolfgang Hofmann to its Supervisory Board and a cooperation agreement with key shareholder MAK Capital, aiming to strengthen governance and shareholder dialogue.


check_boxKey Events

  • New Supervisory Board Nomination

    Dr. Wolfgang Hofmann has been nominated for election as an independent member of the Supervisory Board at the upcoming Annual General Meeting (AGM) on June 11, 2026. This aims to enhance oversight and governance capabilities with additional industry, scientific, and governance expertise.

  • Cooperation Agreement with Key Shareholder

    Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a key shareholder, following constructive discussions. The agreement includes customary voting and cooperation commitments, reflecting Evotec's commitment to open shareholder dialogue and supporting the company's long-term success.

  • Proposed Board Expansion

    The AGM agenda also includes a proposal to increase the size of the Supervisory Board from six to seven members, further supporting effective oversight and long-term value creation.


auto_awesomeAnalysis

Evotec SE's nomination of Dr. Wolfgang Hofmann as an independent Supervisory Board member, alongside the previously announced nomination of Dieter Weinand as Chairman, signals a concerted effort to strengthen corporate governance and oversight. Crucially, the cooperation agreement with key shareholder MAK Capital Fund LP, following constructive discussions, indicates a proactive approach to shareholder relations and aims to ensure stability and alignment with significant investors. This move supports the company's ongoing transformation plans and long-term value creation by fostering a collaborative environment with its shareholders.

At the time of this filing, EVO was trading at $3.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.31 to $4.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EVO - Latest Insights

EVO
May 01, 2026, 5:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
EVO
Apr 30, 2026, 11:48 AM EDT
Filing Type: 6-K
Importance Score:
7
EVO
Apr 24, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
7
EVO
Apr 08, 2026, 11:56 AM EDT
Filing Type: 6-K
Importance Score:
8
EVO
Apr 08, 2026, 11:52 AM EDT
Filing Type: 20-F
Importance Score:
8
EVO
Apr 07, 2026, 12:44 PM EDT
Filing Type: 6-K
Importance Score:
9
EVO
Apr 06, 2026, 12:56 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
EVO
Mar 30, 2026, 8:29 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
EVO
Mar 10, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
9
EVO
Jan 16, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7